2-acetylpyrrole : A pyrrole carrying an acetyl substituent at the 2-position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 14079 |
| CHEMBL ID | 1414126 |
| CHEBI ID | 59981 |
| SCHEMBL ID | 150349 |
| SCHEMBL ID | 8153085 |
| MeSH ID | M0145957 |
| Synonym |
|---|
| 2-acetyl pyrrole |
| 9k28w7pm6n , |
| unii-9k28w7pm6n |
| 5-21-07-00204 (beilstein handbook reference) |
| pyrrole-b-methyl ketone |
| ketone, methyl pyrrol-2-yl |
| nsc42861 |
| 2-acetylpyrrole |
| nsc-42861 |
| methyl pyrrol-2-yl ketone |
| SDCCGMLS-0066967.P001 |
| 1-(2-pyrrolyl)-1-ethanone |
| brn 0001882 |
| 2-acetyl-1h-pyrrole |
| 2-pyrrolylethanone |
| einecs 214-016-2 |
| fema no. 3202 |
| 1-(1h-pyrrol-2-yl)ethan-1-one |
| ccris 6778 |
| 2-pyrrolyl methyl ketone |
| nsc 42861 |
| methyl 2-pyrryl ketone |
| BSPBIO_003593 |
| inchi=1/c6h7no/c1-5(8)6-3-2-4-7-6/h2-4,7h,1h |
| 1-(1h-pyrrol-2-yl)ethanone |
| 1072-83-9 |
| ethanone, 1-(1h-pyrrol-2-yl)- |
| methyl 2-pyrrolyl ketone, >=98%, fg |
| AI-942/25034253 |
| 2-acetylpyrrole, reagentplus(r), 99% |
| NCGC00095914-01 |
| KBIO3_003031 |
| SPECTRUM3_001993 |
| SPBIO_002051 |
| SPECTRUM2_001956 |
| SPECTRUM240422 |
| NCGC00095914-02 |
| A0894 |
| CHEBI:59981 , |
| 1-(1h-pyrrole-2-yl)-ethanone |
| 1-(1h-pyrrol-2-yl)1-ethanone |
| pyrrole-alpha-methyl ketone |
| STK801458 |
| AKOS000120308 |
| NCGC00095914-03 |
| dtxcid8027084 |
| dtxsid0047084 , |
| cas-1072-83-9 |
| NCGC00254854-01 |
| tox21_300952 |
| CHEMBL1414126 |
| methyl 2-pyrrolyl ketone |
| 1-(1h-pyrrol-2-yl)-ethanone |
| BBL010104 |
| CCG-39485 |
| FT-0610982 |
| EPITOPE ID:136036 |
| 2-acetylpyrrole [fcc] |
| methyl 2-pyrrolyl ketone [fhfi] |
| AM90575 |
| SCHEMBL150349 |
| SCHEMBL8153085 |
| 2-acetyl-pyrrole |
| 1-(1h-pyrrol-2-yl)ethanone # |
| 1h-pyrrole, 2-acetyl |
| ethanone, 1-(1h-pyrrole-2-yl)- |
| pyrrole, 2-acetyl |
| pyrrole-.alpha.-methyl ketone |
| Q-200225 |
| BS-3734 |
| F8889-9291 |
| 2-acetyl-1h-indole |
| mfcd00005220 |
| 2-acetylpyrrole, analytical standard |
| SR-05000002372-1 |
| sr-05000002372 |
| 2-acetylpyrrole, vetec(tm) reagent grade, 98% |
| 1-(1h-pyrrol-2-yl)ethanone, 9ci |
| pyrryl-alpha-methyl ketone |
| pseudoacetylpyrrole |
| fema 3202 |
| 1-(1h-pyrrol-2-yl)ethanone (acetylpyrrole) |
| 2-acetopyrrole |
| SY011279 |
| Z56899162 |
| F14878 |
| Q27127005 |
| CS-W013672 |
| EN300-17239 |
| 2-acetopyrrole; 2-pyrrolyl methyl ketone; ethanone, 1-(1h-pyrrol-2-yl)-; methyl 2-pyrrolyl ketone |
| A895652 |
| SB63880 |
| HY-W012956 |
| PD002086 |
| Class | Description |
|---|---|
| pyrroles | An azole that includes only one N atom and no other heteroatom as a part of the aromatic skeleton. |
| methyl ketone | A ketone of formula RC(=O)CH3 (R =/= H). |
| aromatic ketone | A ketone in which the carbonyl group is attached to an aromatic ring. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 41.1999 | 0.0008 | 17.5051 | 59.3239 | AID1159531 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 48.5577 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
| activating transcription factor 6 | Homo sapiens (human) | Potency | 61.6448 | 0.1434 | 27.6121 | 59.8106 | AID1159516 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 61.1306 | 0.0003 | 23.4451 | 159.6830 | AID743065 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID977599 | Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID977602 | Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID1159550 | Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening | 2015 | Nature cell biology, Nov, Volume: 17, Issue:11 | 6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (10.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (41.34) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (10.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (90.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||